Navigation Links
Personalized medicine eliminates need for drug in 2 children
Date:1/31/2013

pertension induced by fludrocortisone and allowing the patients and their family to feel more confident about the origin of the disease, the investigators' discovery made it possible to reduce by as much as $10,000 the health costs for patients with this type of adrenal insufficiency. Over a 70-year lifespan, this is what the fludrocortisone treatment and the blood tests required in the patients treated with it adds up to.

The physicians did not modify the treatment earlier in the children's lives due to lack of a clear molecular diagnosis hence an imperfect understanding of the disease. Not only could withholding one of the replacement hormones have potentially led to a fatal outcome, but also analyzing the whole genome that led to the diagnosis would have been unthinkable just a few years ago. "Due to the astronomical costs associated previously with analyzing the whole genome, certain genes had to be targeted that were potentially responsible for the disorder and only these genes were analyzed in spite of the risk of not finding the right gene," explains Dr. Samuels, a researcher in human genetics. Today, lower genome analysis costs make an analysis of the whole genome affordable.

Description of the study

The two children in the study were hospitalized at the ages of 4 months or 4 years respectively, for hypoglycemia and associated convulsions. A diagnosis of adrenal insufficiency was made and the two children were saved by administering replacement hormones. Their ACTH (the pituitary hormone that controls the adrenal gland) blood concentrations were very high, which seemed to implicate the adrenal gland. The adrenal gland produces two vital hormones: cortisol to regulate glycemia and aldosterone to control minerals. When in doubt, in the event of adrenal insufficiency, both hormone types (cortisol and fludrocortisone, an aldosterone analogue) are prescribed. Nevertheless, fludrocortisone treatment can lead to side effects such as hyp
'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Report from the front lines of personalized reproductive medicine revolution
2. BodyMedia & FitOrbit Up the Ante in Personalized Weight Loss
3. Study advances use of stem cells in personalized medicine
4. Scanning innovation can improve personalized medicine
5. Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine
6. How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment
7. Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
8. Chromosomal translocations point the way toward personalized cancer care
9. Advances in personalized medicine for lung cancer
10. Beers bitter compounds could help brew new medicines
11. Microdosing: Updating its role in developing new medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... fight against the deadly Hendra virus following the development of ... of people who become infected with the virus. ... that administering human monoclonal antibodies after exposure to Nipah virus, ... challenge in a disease model. According to CSIRO,s Dr ...
... SCM Microsystems, Inc. (Nasdaq: SCMM ) (Prime Standard: ... identity and secure exchange, announced today that its stockholders have ... during yesterday,s annual meeting of stockholders. , At ... of SCM,s stockholders cast their votes and a majority followed ...
... that around 2.4 billion years ago, the Earth,s atmosphere ... Called the "Great Oxidation Event" (GOE), the oxygen ... transformation from an oxygen-poor atmosphere to an oxygen-rich one ... the planet. Two questions that remain unresolved in ...
Cached Biology News:Breakthrough in fight against Hendra virus 2SCM Microsystems Announces Results of Annual Meeting 2A new wrinkle in ancient ocean chemistry 2A new wrinkle in ancient ocean chemistry 3
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... out of the desert floor at a place called Ash Meadows, ... found nowhere else in the world. A new Brigham Young ... completing a 15,000-year journey, flowing slowly underground from what is now ... there for four decades, and a crack in the Earth,s crust ...
... , June 17 On Friday June 11th , ... for the District of Delaware issued an important pre-trial ruling ... , , , ... defined several key phrases contained in Roquette,s patent claims, thereby dealing a ...
... ... have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon ... ... Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown ...
Cached Biology Technology:SPI Pharma Gains Ground in Roquette Patent Dispute 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 3
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
NAP-2 (5C7)...
... The CellSensor CRE-bla HEK 293T cell ... control of the cAMP response element (CRE). ... construct was transduced into HEK 293T cells ... to isolate clones responsive to forskolin stimulation ...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Biology Products: